Literature DB >> 26893762

Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report.

Gyeongmin Jeong1, Jinhyong Kim1, Seeun Han1, Jongmin Lee1, Kyunghye Park1, Chuiyong Pak1, Ji-Hun Lim2, Hee Jeong Cha3, Hawk Kim4, Jae-Cheol Jo4.   

Abstract

Myeloproliferative neoplasms are associated with lymphoproliferative diseases following the administration of cytotoxic drugs or exposure to radiation, but are rare prior to therapy. The present study reports the case of a 61-year-old female with a history of transient ischemic attack. The patient, who presented with a palpable mass in the epitrochlear area of the left arm, was simultaneously diagnosed with follicular lymphoma and an unclassifiable myeloproliferative neoplasm. Excisional lymph node biopsy revealed stage I follicular lymphoma (grade 1). Laboratory findings demonstrated leukocytosis, erythrocytosis, thrombocytosis and decreased erythropoietin. Biopsy of the bone marrow revealed hypercellularity, with predominance of erythroid cells, and large polylobated megakaryocytes with increased mitotic figures, but no evidence of lymphomatous infiltration. The janus kinase 2 V617F mutation was also detected in the cells derived from the bone marrow specimen. Following local excision of the lymph node in the left epitrochlear area, radiation was delivered to the involved field, at a dose of 24 Gy in 12 fractions. The patient was started on hydroxyurea (1 g twice per day, orally) 2 weeks subsequent to radiotherapy, and was administered 500 mg twice per day as maintenance therapy. At the six-month follow-up, the white blood cell count, hemoglobin levels and platelet count had reduced, and the patient was in a healthy condition. A computed tomography scan of the neck, chest and abdomen indicated no abnormalities. To the best of our knowledge, the present study is the first case report of follicular lymphoma coexisting with an unclassifiable myeloproliferative neoplasm in a previously healthy patient. Molecular and genetic studies are required to further evaluate this infrequent disease association.

Entities:  

Keywords:  coexistence; follicular lymphoma; unclassifiable myeloproliferative neoplasm

Year:  2015        PMID: 26893762      PMCID: PMC4734269          DOI: 10.3892/ol.2015.4040

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Complications and causes of death in polycythaemia vera.

Authors:  E CHIEVITZ; T THIEDE
Journal:  Acta Med Scand       Date:  1962-11

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

4.  Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.

Authors:  E Montefusco; F Fazi; I Cordone; C Ariola; M Nanni; A Spadea; M A Spiriti; S Fenu; F Mandelli; M C Petti
Journal:  Leuk Lymphoma       Date:  2001-02

5.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Authors:  Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

6.  Platelet activation and inhibition in polycythemia vera and essential thrombocythemia.

Authors:  Carlo Patrono; Bianca Rocca; Valerio De Stefano
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

7.  Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi; Giovanna Masala; Elisabetta Antonioli; Maria Chiara Susini; Paola Guglielmelli; Lisa Pieri; Laura Maggi; Saverio Caini; Domenico Palli; Costanza Bogani; Vanessa Ponziani; Alessandro Pancrazzi; Francesco Annunziato; Alberto Bosi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-16       Impact factor: 4.254

8.  Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

Authors:  Jonathan W Friedberg; Michelle Byrtek; Brian K Link; Christopher Flowers; Michael Taylor; John Hainsworth; James R Cerhan; Andrew D Zelenetz; Jamie Hirata; Thomas P Miller
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

9.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

10.  Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy.

Authors:  Ranjana Advani; Saul A Rosenberg; Sandra J Horning
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more
  1 in total

1.  Clinical significance and epidemiological evolution of epitrochlear lymphadenopathy in pre- and post-highly active antiretroviral therapy era: A systematic review of the literature.

Authors:  Valliappan Muthu; Inderpaul Singh Sehgal; Sahajal Dhooria; Ritesh Agarwal
Journal:  Lung India       Date:  2018 Mar-Apr
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.